RET V738A

CI-VAR-00004610Explore in graph →CIViC 3230

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
RET V738A	Pralsetinib + SelpercatinibSubstitutes	Predictive	D	Supports Resistance	3	submitted	EID8922 Cell line analyses using random mutation libraries identified four selpercatinib-resistant mutations and generation of selpercatinib-resistant cell lines by stepwise drug increase identified another R… (full text at CIViC) PMID 33161056 · Subbiah et al., 2021 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.